ArticleJPGN reports2026
Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single-centre Australian experience.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the durability and predictors of loss of response of infliximab (IFX) over 2 years in paediatric Crohn's disease (CD) utilizing a proactive therapeutic drug monitoring (TDM) strategy. Methods: A retrospective, single-centre cohort study was conducted at The Children's Hospital at Westmead (CHW), Australia, from January 2019 to December 2021. Proactive TDM was performed at induction, end of induction and 6-monthly thereafter. The primary outcome was switching to a different biologic as a marker of treatment failure. Secondary outcomes of a physician global assessment (PGA) scale, calprotectin, albumin and C-reactive protein (CRP) levels were collected at induction, end of induction, 1-year and 2-year timepoints. Results: Seventy-nine patients were included (62% male, median age 13 years). Durability was 96% at 1 year and 88% at 2 years. Nine patients switched biologics with a median time of 57 weeks. Predictors of therapy failure included the need for escalated induction (odds ratio [OR] 8.5, Conclusions: Utilizing a proactive TDM results in excellent durability of IFX at 2 years in paediatric CD. Colonic phenotype is an independent predictor for IFX failure, highlighting the need for directed therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.